Gene Expression Analysis for Statin-induced Cytotoxicity from Rat Primary Hepatocytes |
Ko, Moon-Jeong
(National Institution of Food and Drug Safety Evaluation, Korea Food and Drug Administration)
Ahn, Joon-Ik (National Institution of Food and Drug Safety Evaluation, Korea Food and Drug Administration) Shin, Hee-Jung (National Institution of Food and Drug Safety Evaluation, Korea Food and Drug Administration) Kim, Hye-Soo (National Institution of Food and Drug Safety Evaluation, Korea Food and Drug Administration) Chung, Hye-Joo (National Institution of Food and Drug Safety Evaluation, Korea Food and Drug Administration) Jeong, Ho-Sang (National Institution of Food and Drug Safety Evaluation, Korea Food and Drug Administration) |
1 | Zannis, V.I., Kan, H.Y., Kritis, A., Zanni, E., and Kardassis, D. (2001) .Transcriptional regulation of the human apolipoprotein genes. Front. Biosci. 1, 456-504. |
2 | Luebke-Wheeler, J., Zhang, K., Battle, M., Si-Tayeb, K., Garrison, W., Chhinder, S., Li, J., Kaufman, R.J., and Duncan, S.A. (2008). HNF4 is implicated in ER stress induced acute phase response by regulating expression of CrebH. Hepatology 48, 1242-1250. DOI |
3 | Maddrey, W.C. (2005). Drug-induced hepatotoxicity. J. Clin. Gastroenterol. 39, S83-S89. DOI |
4 | Maitland-van der Zee, A.H., Peters, B.J., Lynch, A.I., Boerwinkle, E., Arnett, D.K., Cheng, S., Davis, B.R., Leiendecker-Foster, C., Ford, C.E., and Eckfeldt, J.H. (2009). The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. Pharmacogenet. Genomics 19, 338-344. DOI |
5 | Hart, S.N., Li, Y., Nakamoto, K., Subileau, E.A., Steen, D., and Zhong, X.B. (2010). A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab. Dispos. March 12, [Epub ahead of print] DOI |
6 | Heart protection study collaborative group. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 360, 7-22. DOI |
7 | Hsu, C.C., Lin, C.C., Liao, T.S., and Yin, M.C. (2006). Protective effect of s-allyl cysteine and s-propyl cysteine on acetaminophen-induced hepatotoxicity in mice. Food Chem. Toxicol. 44, 393-397. DOI |
8 | Johnston, B., Burns, A.R., Suematsu, M., Issekutz, T.B., Woodman, R.C., and Kubes, P. (1999). Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1. J. Clin. Invest. 10, 1269-1276. |
9 | Kanehisa, M., and Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucl. Acids Res. 28, 27-30. DOI |
10 | Mi, H., Lazareva-Ulitsky, B., Loo, R., Kejariwal, A., Vandergriff, J., Rabkin, S., Guo, N., Muruganujan, A., Doremieux, O., Campbell, M.J., Kitano, H., and Thomas, P.D. (2005). The PANTHER database of protein families, subfamilies, functions and pathways. Nucl. Acids Res. 33, D284-D288. DOI |
11 | Stein, E., Sprecher, D., Allenby, K.S., Tosiello, R.L., Whalen, E., and Ripa, S.R. (1997). Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: Effect of 0.2mg daily in subjects with primary hypercholesterolemia. J. Cardiovasc. Pharmacol. Ther. 2, 7-16. DOI |
12 | Vasudevan, A.R., Hamirani, Y.S., and Jones, P.H. (2005). Safety of statins: effect on muscle and the liver. Cleve. Clin. J. Med. 72, 990-993. DOI |
13 | Wilmshurst, P. (2002). Heart Protection Study. Lancet. 2003 Feb 8;361, 528-529 author reply 529-530. DOI |
14 | Yamazaki, H., Suzuki, M., Alki, T., Morikawa, S., Maejima, T., and Sato, F. (2006). Influence of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors of ubiquinone level in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cell. J. Atheroscler. Thromb. 13, 295-307. DOI |
15 | Bolego, C., Baetta, R., Bellosta, S., Corsini, A., and Paoletti, R. (2002). Safety Considerations for statins. Curr. Opin. Lipidol. 13, 637-644. DOI |
16 | Chalasani, N. (2005). Statins and Hepatotoxicity: Focus on patients with fatty liver. Hepatology 41, 690-695. DOI |
17 | Dold, S., Laschke, M.W., Lavasani, S., Menger, M.D., Jeppsson, B., and Thorlacius, H. (2009). Simvastatin protects against cholestasis-induced liver injury. Br. J. Pharmacol. 156, 466-474. DOI |
18 | Hamelin, B.A., and Turgeon, J. (1998). Hydrophilicity/lipophilicity: relevance fro the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19, 26-37. DOI |
19 | Baycol website. Dear healthcare Letter Baycoll pull.jpg http://www.baycol.com/. |
20 | Ahn, J., Jeong, K.J., Ko, M., Shin, H.J., Chung, H.J., and Jeong, H. (2009). High-concentration Epigallocatechin gallate treatment causes endoplasmic reticulum stress-mediated cell death in HepG2 cells. Genomics inform. 7, 97-106. DOI |
21 | Bharadwaj, D., Stein, M.P., Volzer, M., Mold, C., and Du Clos, T.W. (1999). The major receptor for C-reactive protein on leukocytes is fcgamma receptor. J. Exp. Med. 16, 585-590. |